Molecular Diagnostic Solutions
BD offers a comprehensive molecular diagnostics ecosystem—designed to support labs across testing volumes, workflows, and clinical needs.
- For Labs
The challenges diagnostics faces today
Modern testing environments are under unprecedented strain—clinically, operationally, and financially.
- Rising rates of infectious diseases and evolving guidelines demand faster, more precise diagnostics
- Overlapping symptoms make accurate diagnosis difficult with traditional testing methods
- Delayed or inaccurate results put patients at risk and can contribute to disease spread
- Manual workflows increase error risk and staff fatigue
- Fragmented platforms create inefficiencies and bottlenecks
- Laboratories struggle to balance routine, high volume testing with stat and specialized needs
- Reimbursement reductions and denied claims erode margins
- Staffing shortages drive burnout, turnover, and rising operational costs
- Capital and lab space constraints limit growth
Why molecular diagnostics matter
Molecular diagnostics have transformed how laboratories detect and manage disease—providing actionable insights that go beyond traditional methods.
-
Higher sensitivity and specificity for earlier, more confident diagnosis
-
Fast turnaround times to support timely clinical decision‑making
-
Targeted testing that aligns with diagnostic stewardship and reimbursement expectations
-
Automation and standardization to reduce hands‑on time and error risk
Modern labs don’t operate at a single speed—and neither should their molecular solutions.
BD Molecular Instruments are designed to work together, allowing labs to route each sample to the right system based on urgency, volume, and testing requirements. The result is a unified molecular ecosystem that balances efficiency, flexibility, and clinical excellence.
A Molecular Portfolio Built for the Real World
BD offers a comprehensive molecular diagnostics ecosystem—designed to
support labs across testing volumes, workflows, and clinical needs.
BD COR™ System
High‑Throughput Automation Without Compromise
The BD COR™ System is a fully automated, high‑throughput molecular solution designed to scale routine testing while protecting staff time and lab resilience.Key strengths:
- End‑to‑end automation from pre‑analytics to result
- High‑volume processing for routine screening and population‑level testing
- Modular design allows configuration tailored to lab needs
- Powered by BD Synapsys™ Informatics for streamlined workflows
Ideal for:
- High‑volume molecular programs, standardized screening, and labs focused on operational efficiency at scale.
BD MAX™ System
Agile, Mid Throughput Molecular Testing
The BD MAX™ System is a flexible, intuitive molecular platform built for precision, speed, and simplicity.Key strengths:
- Mid throughput testing with fast turnaround times
- Broad FDA cleared assay menu across sexual health, respiratory, enterics, and HAIs
- Ability to run a single or batch of samples—without reagent waste
- Intuitive, walkaway workflow with minimal hands on time
- Open system capability for laboratory developed tests
Ideal for:
Urgent testing, low to moderate volumes, menu expansion, lab developed testing
BD Viper™ LT System
Precision HPV Testing Without Added Complexity
Dedicated, fully automated molecular solution designed to deliver advanced HPV testing insights with the BD Onclarity™ HPV Assay.1The only FDA approved HPV test solution that combines individual extended HPV genotyping beyond HPV 16, 18 and 45 with reliable automation—helping labs support guidelines and risk-based patient management without increasing operational burden.1,2,3
Key strengths:
- Fully automated molecular testing that saves time and space with a compact, self-contained table-top unit for sample to result HPV testing1
- Supports the BD Onclarity™ HPV Assay, the only FDA approved HPV test that supports all of the ASCCP Enduring Risk Based Management Guidelines.3
- Provides flexible testing options with FDA approval for reflex testing, co-testing, primary screening and the guidelines-supported option on self-collection.4,5,6,7*
- Accepts BD SurePath™ , Hologic ThinPrep® cytology specimen types, and self-collected vaginal swabs for collection flexibility1
- Minimal hands-on time with walk away operation to optimize daily throughput
- Up to 30 sample results in 4.5 hours1
- <20 minutes of total hands-on time per run1
Ideal for:
Cervical cancer screening programs, women’s health laboratories, and labs seeking a dedicated, efficient HPV testing solution that enables risk-based clinical decision making without added complexity.
BD Totalys™ MultiProcessor and BD Totalys™ Slideprep System for BD SurePath
Automated Confidence for Cytology and HPV Workflows
The BD Totalys™ MultiProcessor combines full automation of the cell enrichment process for cervical samples, rigorous chain of custody and customizable aliquots for ancillary testing.
Key strengths:
- Automated sample transfer, centrifugation, aspiration and decanting for cytology processes minimize hands-on time.
- LIS integration provides positive sample identification to downstream diagnostic systems.
- Complements the BD SurePath™ liquid-based Pap test.
- Features an optional aliquot to secondary vials for ancillary testing.
The BD Totalys™ SlidePrep maintains continuous chain of custody through integration with the BD Totalys™ MultiProcessor.
Key strengths:
- Provides full chain of custody by automatically scanning each slide and matching it to the associated sample.
- A graphical interface with a touch screen walks users through every step and offers random loading to reduce manual steps.
- Allows you to process BD SurePath™ liquid-based Pap test and non-gyn samples on the same system with additional parameter flexibility.
- Offers bulk reagent and waste management including calculated level detection.
Ideal for:
Cervical cancer screening programs, cytology‑driven and women’s health laboratories, and high‑volume environments
Learn More about the BD Totalys™ SlidePrep and BD Totalys™ Multiprocessor Systems
BD Molecular Diagnostic Assays
Comprehensive Testing for Critical Disease States
BD Molecular Diagnostic assays address the most pressing clinical challenges with clinically relevant assays.Women’s Health
- BD Onclarity™ HPV Assay is the only FDA approved HPV test with both self-collection* option and extended genotyping beyond 16, 18, and 45 – Learn More
- BD Vaginal Panel and BD CTGCTV2 provide objective vaginitis and STI results that strategically inform therapeutic choices from a single patient sample – Learn More
- BD GBS Assay delivers timely and accurate Group B Strep screening results in newborn babies – Learn more
Enterics
The BD Enteric portfolio delivers targeted syndromic testing for complex GI infections. Learn more
- Enteric Bacterial Panels
- Enteric Parasite Panel
- Enteric Viral Panel
Respiratory
- Helps address and contain the spread of respiratory infections with accurate and timely testing of SARS-COV-2, Flu A and B, and RSV. Learn more
Healthcare Associated Infections
- Delivers rapid, reliable diagnostics for leading HAI challenges enabling timely, informed decisions for treatment of C. difficile, MRSA, StaphSR, and CPO. Learn more
*Self-collected vaginal specimens can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.
One partner. One ecosystem.
With BD’s molecular diagnostics portfolio, labs gain more than instruments—they gain a strategic partner.
- Unified service, training, and support
- Consistent workflows and informatics through BD Synapsys™
- A scalable platform that evolves as testing needs change
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
1. BD Viper™ LT System User’s Manual 500005363(09) 2021-10
2. BD Onclarity™ HPV Assay Package Insert 8089894(09) 2024-07
3. ASCCP Guidelines: Journal of Lower Genital Tract Disease ():10.1097, January 10, 2025.
4. Wentzensen N, Massad LS, Clarke MA, et al. Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. J Low Genit Tract Dis. 2025;29(2):144-152.
5. ACS: Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041
6. HRSA: Women’s Preventive Services Guidelines | HRSA accessed February 2026.
7. ACOG: ACOG Statement issued January 5th, 2026.
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.
Thank you for your interest in how BD can support your efforts to address infection risk factors.
A BD associate will be in touch to discuss how we can help.
